Skip to main content
Log in

The Effect of Medicaid Formularies on the Availability of New Drugs

  • Medicaid Formularies and New Drug Availability
  • Pharmaco Economics
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Summary

This study expands our previous work on the availability of new drug introductions to poor patients in states in the USA with restrictive Medicaid formularies. In particular. it focuses on the experience of 9 states over the period 1979 to 1985. In these states. a typical new drug took 20 months after FDA approval to gain acceptance onto the Medicaid formulary. New drug introductions were available to Medicaid patients less than 40% of the time during their first 4 years of market life. Restrictions on availability also extended to drugs ranked high in terms of both therapeutic and commercial importance. There was substantial variation observed across states and therapeutic categories. While formularies are prohibited under legislation recently enacted by the US Congress. state governments may attempt to continue to restrict access to expensive new medicines through prior approval systems. This is an issue that warrants future attention and study.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Grabowski, H.G., Schweitzer, S.O. & Shiota, S.R. The Effect of Medicaid Formularies on the Availability of New Drugs. Pharmacoeconomics 1 (Suppl 1), 32–40 (1992). https://doi.org/10.2165/00019053-199200011-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199200011-00009

Keywords

Navigation